Minerva Neurosciences (NERV) Other Non Operating Income (2013 - 2026)
Minerva Neurosciences' (NERV) quarterly Other Non Operating Income came in at -$1804.0 in Q1 2026, up 78.46% YoY from -$1010.9 in Q1 2025, and up 91.34% on a QoQ basis from -$20823.0 in Q4 2025.
Powered by 
Analysis
Minerva Neurosciences (NERV) Other Non Operating Income (2013 - 2026) Analysis & Trends
Minerva Neurosciences (NERV) has 14 years of Other Non Operating Income data on file, last reported at -$1804.0 in Q1 2026.
- Quarterly Other Non Operating Income rose 78.46% year-over-year to -$1804.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$49983.0 (down 216.45% YoY) and the FY2025 annual result came in at -$56555.0, down 2836.4% from the prior year.
- Other Non Operating Income rose to -$1804.0 in Q1 2026, from -$20823.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $10383.0 in Q4 2024 to a low of -$27606.0 in Q4 2022.
- A 5-year average of -$7544.8 and a median of -$6246.0 in 2025 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2022 — Other Non Operating Income sank 567.13% — and 2024, when it jumped 163.24%.
- Tracing NERV's Other Non Operating Income over 5 years: stood at -$27606.0 in 2022, then surged by 30.28% to -$19247.0 in 2023, then jumped by 153.95% to $10383.0 in 2024, then sank by 300.55% to -$20823.0 in 2025, then surged by 91.34% to -$1804.0 in 2026.
- The last three Other Non Operating Income figures came in at -$1804.0 (Q1 2026), -$20823.0 (Q4 2025), and -$6246.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn |
| 10 | Minerva Neurosciences | 210.16 Mn | 210.16 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -14,351.00 |
| Mar 31, 2026 | -1,804.00 |
| Dec 31, 2025 | -20,823.00 |
| Sep 30, 2025 | -6,246.00 |
| Jun 30, 2025 | -21,110.00 |
| Mar 31, 2025 | -8,376.00 |
| Dec 31, 2024 | 10,383.00 |
| Sep 30, 2024 | -13,108.00 |
| Jun 30, 2024 | -4,694.00 |
| Mar 31, 2024 | 5,493.00 |
| Dec 31, 2023 | -19,247.00 |
| Sep 30, 2023 | -5,096.00 |
| Jun 30, 2023 | -7,206.00 |
| Mar 31, 2023 | -8,686.00 |
| Dec 31, 2022 | -27,606.00 |
| Sep 30, 2022 | 2,063.00 |
| Jun 30, 2022 | 1,596.00 |
| Mar 31, 2022 | -3,794.00 |
| Dec 31, 2021 | -1.14 Mn |
| Sep 30, 2021 | -4,855.00 |